News Channels

28 Nov 2018 FDA Clears SpinalCyte IND Application for Universal Donor Cell Therapy to Treat Lower Back Pain
28 Nov 2018 Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human Anti-Cluster Definition 3 Monoclonal Antibody (anti-CD3 mAb), in Healthy Volunteers
28 Nov 2018 Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)
28 Nov 2018 Generex Biotechnology Signs Clinical Trial Agreement With the NSABP Foundation, Inc. for Phase II Clinical Trial of AE37 in Combination With Pembrolizumab (Keytruda®) for Treatment of Triple-Negative Breast Cancer
28 Nov 2018 Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease
28 Nov 2018 Augie's Quest Reports First Subject Successfully Enrolled in AT-1501 Phase 1 Study, a First-of-its-Kind, Promising Treatment for ALS
28 Nov 2018 PhaseBio Announces Dosing of First Patient in Phase 2b Clinical Trial of PB1046 in Pulmonary Arterial Hypertension
28 Nov 2018 Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy
28 Nov 2018 Arsanis and X4 Pharmaceuticals Agree to Merger
28 Nov 2018 Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers
28 Nov 2018 Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma
28 Nov 2018 ONO Submits an Application for Manufacturing and Marketing Approval of Anamorelin (ONO-7643), a ghrelin receptor antagonist, for the treatment of cancer cachexia in Japan
28 Nov 2018 Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam)
28 Nov 2018 Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy
28 Nov 2018 Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally
28 Nov 2018 Genentech Acquires Jecure Therapeutics
28 Nov 2018 Primary endpoint met in phase III clinical study of Fycompa® as monotherapy for partial-onset seizures aiming for submission in Japan
28 Nov 2018 Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS
28 Nov 2018 European Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib, Advancing Treatment Paradigm in Europe
28 Nov 2018 Bayer receives EU approval for its hemophilia A treatment Jivi®

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up